FDA Chief Vinay Prasad Resigns Amidst Controversies

Dr. Vinay Prasad, Chief Officer of the Food and Drug Administration (FDA), resigned unexpectedly after less than three months of federal employment. 

The Details: Prasad disputed with biopharmaceutical company Sarepta Therapeutics by opposing the gene therapy Elevidys, a Duchenne Muscular Dystrophy (DMD) treatment. In response to both the dispute and other controversies, MAGA activist Laura Loomer accused Prasad of being a “Progressive Leftist Saboteur” working against the Make America Healthy Again (MAHA) movement and President Donald Trump’s corresponding agenda. 

For Context: FDA Commissioner Marty Makary named Prasad director of the Center for Biologics Evaluation and Research in May and Chief Medical and Science Officer in June. Prasad was a known skeptic of COVID-19-era policies and vaccine side effects prior to his federal employment. 

Key Quote: A Department of Health and Human Services (HHS) spokesperson stated, “Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration.” Prasad himself did not release any public commentary, and a replacement has not been named at the time of this publishing. 

How The Media Covered It: Left and Center-rated outlets covered Prasad’s departure more prominently than outlets on the right. However, outlets across the political spectrum covered the news similarly. Washington Examiner (Lean Right bias) and Associated Press (Left) focused more on Loomer’s role in Prasad’s resignation, framing her as having an integral role in multiple other resignations or firings of Trump administration officials. The Examiner and The Hill (Center) highlighted comments Makary made this month in favor of Prasad. AP also framed Prasad as being at odds with Trump’s “Right to Try” law that “allows eligible patients to request access to certain investigational drugs that have not yet been approved by the FDA.”

Revised by the AllSides staff (of humans) after a first draft from our custom AI. Learn more. Support our mission. Suggest an improvement to this summary.